Company
Shanghai Fosun Pharmaceutical
Shanghai Fosun Pharmaceutical has 29 drugs tracked on RxWires: 6 approved, 5 in Phase 3, 2 in Phase 2/3, 7 in Phase 2, 1 in Phase 1/2, 8 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| BUPRENORPHINE | Approved | |
| RISEDRONATE SODIUM | Approved | |
| DESVENLAFAXINE | Approved | |
| NOREPINEPHRINE BITARTRATE | Approved | |
| ESZOPICLONE | Approved | |
| ACETAMINOPHEN AND CODEINE PHOSPHATE | Approved | |
| Test group (Group A): FCN-159 8 mg, orally, once daily; | Phase 3 | Neurofibromatosis 1 |
| Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502) | Phase 3 | Breast Cancer |
| Rituximab | Phase 3 | Idiopathic Membranous Nephropathy |
| FXS6837 Capsule | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| Luvometinib | Phase 3 | Low-grade Glioma |
| Azvudine | Phase 2/3 | SARS-CoV-2 Infection |
| Intervention1: FXS5626 Tablets | Phase 2/3 | Non-segmental Vitiligo |
| FCN-159 | Phase 2 | Langerhans Cell Histiocytosis |
| luvometinib + anlotinib | Phase 2 | Non-small Cell Lung Caner |
| XH-S003 Capsule | Phase 2 | IgA Nephropathy |
| FXS6837 Dose 1 | Phase 2 | IgAN |
| FXS5626 tablet | Phase 2 | Active Non-anterior, Non-infectious Uveitis |
| FCN-338 + Azacitidine | Phase 2 | Safety |
| Argesun 60mg (1 step parenteral artesunate) | Phase 2 | Severe Malaria |
| Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI | Phase 1/2 | Colorectal Cancer |
| XS-04 tablet | Phase 1 | B-cell Lymphoma |
| [¹⁴C]FXS4640 | Phase 1 | Healthy Subjects |
| FN-1501 | Phase 1 | Advanced Cancer |
| XS-02 capsules | Phase 1 | Solid Tumor |
| FXS0683 | Phase 1 | B-Cell Lymphoma |
| FXS887 | Phase 1 | Solid Tumor Refractory to Conventional Treatment |
| FS-1502 | Phase 1 | Solid Tumor |
| Intervention1：FXB0871 | Phase 1 | Solid Tumors |
Latest
- Boxed warning added: BUPRENORPHINE
- Label updated: ESZOPICLONE
- Label updated: BUPRENORPHINE AND NALOXONE
Follow Shanghai Fosun Pharmaceutical on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.